Pathological changes in prostate lesions after androgen manipulation

Journal of Clinical Pathology

Volumn 51, Issue 1, 1998, Pages 5-12

  Montironi, R ^a   Schulman, C C ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Androgens; Neoadjuvant hormonal treatment; Prostate cancer; Radical prostatectomy

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; AGING; ARTICLE; CANCER GRADING; CELL DIVISION; EARLY DIAGNOSIS; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STEM CELL;

EID: 0031890876     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.1.5     Document Type: Article

References (45)

1. Watson RB, Soloway MS. Neoadjuvant hormonal treatment before radical prostatectomy. Seminars Urol Oncol 1996;14(suppl 2):48-56.
2. Bostwick DG. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 1996; 30:145-52.
3. Schulman CC, Wildschutz T, Zlotta AR. Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and questions. Eur Urol 1997;32(suppl):41-7.
4. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Sem Surg Oncol 1994;10:60-72.
5. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
6. Epstein JI, Pizov G, Walsh PC. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
7. Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.
8. Fair WR, Aprikian A, Sogani P, et al. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71(suppl):1031-8.
9. Gleave ME, Goldenberg SL, Jones EC, et al. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Sem Urol Oncol 1996;14(suppl 2):39-47.
10. Crawford ED, Eisenburger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
11. Montironi R, Diamanti L. Morphologic changes in benign prostatic hyperplasia following chronic treatment with a 5-α-reductase inhibitor finasteride. Comparison with combination endocrine therapy. J Urol Pathol 1996;4:123-35.
12. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Sem Urol Oncol 1996;14(suppl 2):22-31.
13. Montironi R, Magi Galluzzi C, Scarpelli M, et al. Quantitative characterisation of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem 1994;19(suppl):238-45.
14. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;75:1850-9.
15. Bazinet M, Zheng W, Begin LR, et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 1997; 49:721-5.
16. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E 12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 1995;19:251-60.
17. Akakura K, Bruchovsky N, Goldenberg N, et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 1993;71:2782-90.
18. Ferguson J, Zincke H, Ellison E, et al. Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994;44:91-5.
19. Vaillancourt L, Tetu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. J Surg Pathol 1996;20:86-93.
20. Montironi R, Magi Galluzzi C, Muzzonigro G, et al. Effect of combination endocrine therapy on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13
21. Armas OA, Aprikian A, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy in clinically localized prostatic carcinoma. Am J Surg Pathol 1994;18:979-91.
22. Magi Galluzzi C, Montironi R, Giannulis I, et al. Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol Res Pract 1993;189:1154-60.
23. Montironi R, Magi Galluzzi C, Fabris G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 1995;191:873-80.
24. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991;68:821-8.
25. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997;49(suppl 3A):16-22
26. Smith DM, Murphy WM. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 1994;73:1472-7.
27. Tétu B, Srigley JR, Boivin J-C, et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. Am J Surg Pathol 1991;15:111-20.
28. Van de Voorde WM, Elgamal AA, Van Poppel HP, et al. Morphologic and immunohistochemical changes in prostate cancer aller preoperative hormonal therapy. Cancer 1994;74:3164-75.
29. Gould VE, Doljanskaia V, Gooch GT, et al. Stability of the glycoprotein A-80 in prostatic carcinoma subsequent to androgen deprivation therapy. Am J Surg Pathol 1997;21: 319-26.
30. Schulman CC, Sassine AM. Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 1993;24:450-5.
31. Montironi R, Bartels PH, Thompson D, et al. Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. Eur Urol 1996;30: 307-15.
32. Schulman CC, Witjes WPJ, Zlotta AR, et al, for the European Study Group on Neoadjuvant Treatment of Prostate Cancer. Neoadjuvant combined androgen deprivation therapy in locally confined prostate carcinoma: short-term results of a European randomized study. Molecular Urology. [In press.]
33. Trachtenberg J. Neoadjuvant androgen ablation therapy prior to radical prostatectomy: quantum leap or hope unrealised? Curr Opin Urol 1996;6:254-7.
34. Gleave ME, Goldenberg SL, Jones EC, et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinical confined prostate cancer. J Urol 1995; 155:213-19.
35. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994; 152:1826-30.
36. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996;23:587-604.
37. Fair WR, Cookson MS, Stroumbakis N, et al. The indications rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer. Urology 1997;49(suppl):46-55.
38. Soloway MS, Sharifi R, Wood D, et al. Randomized comparison of radical prostatectomy alone or preceded by androgen deprivation for cT2 prostate cancer. J Urol 1995; 154:424-8.
39. Witjes W, Schulman CC, Forster G, et al, European Study Group on Neoadjuvant Treatment [abstract]. Eur Urol 1996;30(suppl 2):210.
40. Labrie F, Cusan L, Gomez JL, et al. Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing agonist. Urology 1994;44:29-37.
41. Haggman M, Hellstrom M, Aus G, et al. Neoadjuvant GnRH agonist treatment (tryptorelin and cyproterone acetate) for flare protection and total prostatectomy. Eur Urol 1993;24:456-60.
42. Swedish POPCOM Group, Pedersen KV, Lundberg S, Hugosson J, et al. Neoadjuvant treatment with triptorelin versus no treatment prior to radical prostatectomy: a prospective randomized multicenter study [abstract]. J Urol 1995;153(suppl):391.
43. Goldenberg SL, Klotz LH, Jewett MAS, et al, The Canadian Urologic Oncology Group. Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy for prostate cancer. J Urol 1996;156:873-7.
44. Aus G, Abrahamsson PA, Goran A, et al. Pretreatment with triptorelin before radical prostatectomy a 2 year follow-up. Eur Urol 1996;30A(suppl 2):209.
45. Schulman CC. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate 1994;5(suppl):9-13